Does azathioprine cause a higher risk of liver enzyme elevation compared to 6‑mercaptopurine in IBD patients
Out of scope for this tool. The focus of this literature tool is the surgical management of IBD. For medical management and drug dosing, please see ChatIBD.com.
The retrieved excerpts do not establish that azathioprine causes a higher risk of liver enzyme elevation than 6-mercaptopurine; both are consistently described together as thiopurines that share the same hepatotoxic mechanism 1–4. Azathioprine is a prodrug converted to 6-mercaptopurine, and their liver injury. Ranging from asymptomatic enzyme elevation to cholestasis and nodular regenerative hyperplasia. Is attributed to the same downstream metabolite (6-methylmercaptopurine) common to both drugs 2–4. 1–6
What is known: - Azathioprine and its derivative 6-mercaptopurine can cause a spectrum of liver injury from asymptomatic enzyme elevation to cholestasis and nodular regenerative hyperplasia. 1 - Hepatotoxicity with azathioprine or 6-mercaptopurine is driven by the shared metabolite 6-methylmercaptopurine, with risk linked to TPMT activity. 2–4 - Thiopurine hepatotoxicity is reported in roughly 4-14% of treated patients, with most cases transient and resolving with dose adjustment or discontinuation. 4–6
What is unknown / caveats: - Excerpts treat azathioprine and 6-mercaptopurine together and report no head-to-head comparison of enzyme-elevation risk - Reported hepatotoxicity rates are not stratified by individual drug - No excerpt directly compares azathioprine versus 6-mercaptopurine for risk of liver enzyme elevation.
## References
1. Wieser V, Gerner R, Moschen AR, Tilg H. Liver complications in inflammatory bowel diseases. Dig Dis. 2013. PMID: 24030232.
2. Uko V, Thangada S, Radhakrishnan K. Liver disorders in inflammatory bowel disease. Gastroenterol Res Pract. 2012. PMID: 22474447.
3. Losurdo G, Brescia IV, Lillo C, Mezzapesa M, Barone M, Principi M, Ierardi E, Di Leo A, Rendina M. Liver involvement in inflammatory bowel disease: What should the clinician know?. World J Hepatol. 2021. PMID: 34904028.
4. Singh A, Bhardwaj A, Kaur H, Bawa A, Midha V, Sood A. Drug-induced liver injury in inflammatory bowel disease: Challenges in diagnosis and monitoring. World J Hepatol. 2025. PMID: 41479516.
5. Gaspar R, Branco CC, Macedo G. Liver manifestations and complications in inflammatory bowel disease: A review. World J Hepatol. 2021. PMID: 35070000.
6. Kucharska M, Daniluk U, Kwiatek-Średzińska KA, Wasilewska N, Filimoniuk A, Jakimiec P, Zdanowicz K, Lebensztejn DM. Hepatobiliary manifestations of inflammatory bowel disease in children. Clin Exp Hepatol. 2019. PMID: 31598556.
For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.
---
_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._
Reviewer notes